Search Results for 'Treatment of multiple sclerosis'
2 results found.
Good news for Elan as study illustrates Tysabri MS success
Athlone-based drug developer and its US partner, Biogen Idec, last evening hailed success from a study into the effects of their MS drug, Tysabri in repairing damage to the myelin sheath, a key cause of MS.
Elan’s Tysabri lowers Crohn’s hospitalisations
Athlone-based pharmaceutical company, Elan, and its US partner Biogen have announced that their drug Tysabri has been proven to significantly reduce the rate of hospitalisation of patients with moderate-to-severe Crohn’s disease.
